Deep brain stimulation (DBS) from Medtronic safely and effectively manages tremor, rigidity, and bradykinesia associated with Parkinson's disease.1 It may be a therapeutic option for patients with recent or longer-standing motor complications.
Physicians should be aware that the risks associated with initial surgery may increase with clinical conditions3 such as:
To help ensure maximum benefits from the neurostimulation system, long-term, post-surgical management of patients is recommended.
The use of Medtronic DBS therapy for Parkinson’s disease has been studied in 6 large randomised control trials (5 level 1). Download our clinical summary to see the data.
Consider deep brain stimulation when a patient has:
The window of opportunity for your patients to receive DBS therapy begins as early as four years after the appearance of their first Parkinson’s symptoms—so knowing when to have the conversation about further treatment options can make a significant difference in the preservation of your patients’ daily function, and their quality of life.2
Visit the Medtronic EarlyStimulus tool now to find out if your patient may be eligible to begin their DBS journey - before their window of opportunity closes.Visit Earlystimulus site
With the guidance of Medtronic’s EarlystimulusTM tool - based on the RAND/UCLA method - you’ll have actionable, objective information at your fingertips to inform the therapeutic decisions you make with your patients.
Nicky and her family from the UK show how Medtronic deep brain stimulation therapy has improved their lives.
Call UK Technical Services & Mobility Support +44 1923 201 805
Medtronic DBS systems are MR Conditional which means they are safe for MRI scans only under certain conditions. If the conditions are not met, the MRI could cause tissue heating, especially at the implanted lead(s) in the brain, which may result in serious and permanent injury or death. Before having an MRI, always talk with the doctor who manages your DBS Therapy to determine your eligibility and discuss potential benefits and risks of MRI. For further information, please call Medtronic at +44 (0) 1923 205101.
Medtronic DBS Therapy for Parkinson's Disease and Essential Tremor Clinical Summary, 2015.
Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. February 14, 2013; 368:610-622.
Fenoy AJ, Simpson RK. Risks of common complications in deep brain stimulation surgery: management and avoidance. J Neurosurg. 2014;120(1):132-139.
Parkinson’s UK. “Deep Brain Stimulation for Parkinson’s.” Accessed December 10, 2020. https://www.parkinsons.org.uk/sites/default/files/2020-02/B123_DBS_FINAL_WEB.pdf.
Silberstein P, Bittar RG, Boyle R. Deep brain stimulation for Parkinson’s disease: Australian referral guidelines. Journal of Clinical Neuroscience 2009;16:1001-8
Okun MS, Foote KD. Parkinson’s disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Rev Neurother. 2010 December ; 10(12): 1847–1857”
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.